UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
________________________________________
FORM
8-K/A
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
report (Date of earliest event reported): January
1, 2007
CYTOGEN
CORPORATION
________________________________________
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-14879
|
22-2322400
|
||
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
650
College Road East, CN 5308, Suite 3100, Princeton, NJ
|
08540
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (609)
750-8200
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
|
Item
5.02
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers; Compensatory Arrangements of Certain
Officers.
|
This
Form
8-K/A is being filed to correct the calculation of bonus amounts as stated
in the Company's Form 8-K filed on January 4, 2007.
In
connection with its annual performance review process, the Compensation
Committee and the Board of Directors of
Cytogen
Corporation (the “Company”) approved, as of January 1, 2007, the annual
incentive (i.e. cash bonus) awards for the period January 1, 2006 to December
31, 2006 and the annual salaries for 2007 for executive officers of the
Company.
The
annual incentive awards, as shown in the table below, were based on the
Compensation Committee’s assessment of the Company’s and each executive’s
performance measured against previously set financial and strategic
objectives.
The
following table sets forth the cash bonus amounts for 2006 performance and
the
annual base salaries for 2007 for the executive officers (Michael D. Becker,
Kevin J. Bratton, William F. Goeckeler, and William J. Thomas) who will be
included as the Named Executive Officers in the Company’s 2007 proxy
statement.
|
Name
|
Title
|
2006
Bonus
|
2007
Salary
|
|
Michael
D. Becker
|
President
and Chief Executive Officer
|
$180,000
|
$383,720
|
|
Kevin
J. Bratton
|
Senior
Vice President, Finance, and Chief Financial Officer
|
$
20,000
|
$225,000
|
|
William
F. Goeckeler
|
Senior
Vice President, Operations
|
$
91,664
|
$277,156
|
|
William
J. Thomas
|
Senior
Vice President and General Counsel
|
$
66,338
|
$253,386
|
The
named
executive officers do not currently have any employment agreements with the
Company.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CYTOGEN
CORPORATION
|
||
|
By:
|
/s/
William J. Thomas
|
|
|
William
J. Thomas,
|
||
|
Senior
Vice President and General Counsel
|
||
|
Dated:
|
January
19, 2007
|
3